SCHEMBL16482020

SCHEMBL16482020

Cc1nc(-c2c(C)ccnc2Cl)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.45
PIM1 P11309 5/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
CHEK1 O14757 2/20 0.41
CDK2 P24941 2/20 0.41
CSNK2A1 P68400 2/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
KDM4E B2RXH2 1/20 0.40
HCRTR2 O43614 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
EGFR P00533 1/20 0.38
RET P07949 1/20 0.38
ROS1 P08922 1/20 0.38
KIT P10721 1/20 0.38
ACVR1 Q04771 1/20 0.38
PLK1 P53350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16583512 0.78 L3MBTL1 (0.44) NTRK1PIM1L3MBTL1CHEK1CDK2
SCHEMBL16481889 0.76 L3MBTL1 (0.47) NTRK1PIM1L3MBTL1KDM4ENPC1
SCHEMBL16481860 0.75 L3MBTL1 (0.42) NTRK1PIM1L3MBTL1CHEK1CDK2
SCHEMBL16583292 0.75 PIK3CD (0.39) NTRK1PIM1L3MBTL1CHEK1CDK2
SCHEMBL12881070 0.73 L3MBTL1 (0.45) NTRK1PIM1L3MBTL1CHEK1CDK2
SCHEMBL25253195 0.72 L3MBTL1 (0.51) NTRK1PIM1L3MBTL1CA12CA1
SCHEMBL16481893 0.71 L3MBTL1 (0.59) NTRK1PIM1L3MBTL1CA12CA1
SCHEMBL8295451 0.71 L3MBTL1 (0.58) NTRK1PIM1L3MBTL1CA12CA1
SCHEMBL12696334 0.67 L3MBTL1 (0.53) NTRK1PIM1L3MBTL1CHEK1CDK2
SCHEMBL2359857 0.67 NR1H4 (0.66) NTRK1PIM1L3MBTL1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493446-B2 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-11-15 US disclosed
US-9493446-B2 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-11-15 US disclosed
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
WO-2014057435-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES HCRTR2, HCRTR1, OXTR NTRK1 643/4885PIM1 4263/4885L3MBTL1 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.